CA2322663A1 - Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale - Google Patents
Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale Download PDFInfo
- Publication number
- CA2322663A1 CA2322663A1 CA002322663A CA2322663A CA2322663A1 CA 2322663 A1 CA2322663 A1 CA 2322663A1 CA 002322663 A CA002322663 A CA 002322663A CA 2322663 A CA2322663 A CA 2322663A CA 2322663 A1 CA2322663 A1 CA 2322663A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- cell
- vector
- promoter
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne, de manière générale, des vecteurs viraux et leur utilisation comme vecteurs d'expression pour transformer des cellules humaines, in vitro et in vivo. En particulier, la présente invention concerne des vecteurs adénoviraux contenant des gènes propapoptotiques et leur utilisation dans les thérapies anticancéreuses.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7754198P | 1998-03-11 | 1998-03-11 | |
US60/077,541 | 1998-03-11 | ||
PCT/US1999/005359 WO1999046371A2 (fr) | 1998-03-11 | 1999-03-11 | Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2322663A1 true CA2322663A1 (fr) | 1999-09-16 |
Family
ID=22138678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002322663A Abandoned CA2322663A1 (fr) | 1998-03-11 | 1999-03-11 | Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1070122A4 (fr) |
AU (1) | AU762493B2 (fr) |
CA (1) | CA2322663A1 (fr) |
WO (1) | WO1999046371A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4764801A (en) * | 2000-03-24 | 2001-10-08 | Calydon Inc | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US7125549B2 (en) | 2000-05-31 | 2006-10-24 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
US20040091453A1 (en) * | 2000-06-02 | 2004-05-13 | Hiroshi Okamoto | Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
EP1207205A1 (fr) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Réplicons adénoviraux |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
CA2471719A1 (fr) * | 2001-12-31 | 2003-07-17 | Dana-Farber Cancer Institute, Inc. | Methode de traitement de l'apoptose et compositions associees |
JP4511108B2 (ja) | 2002-05-31 | 2010-07-28 | オンコリクス インコーポレイテッド | ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質 |
CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
CN110174456B (zh) * | 2019-06-11 | 2021-09-21 | 华润双鹤药业股份有限公司 | 一种测定肺表面活性物质蛋白的方法及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025507A2 (fr) * | 1995-02-17 | 1996-08-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines |
DE19615803A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Ingelheim Int | CELO-Virus |
WO2000015648A1 (fr) * | 1998-09-10 | 2000-03-23 | The Uab Research Foundation | Vecteur adenoviral codant pour le gene bax pro-apoptotique et utilisations d'un tel vecteur |
-
1999
- 1999-03-11 EP EP99913854A patent/EP1070122A4/fr not_active Withdrawn
- 1999-03-11 WO PCT/US1999/005359 patent/WO1999046371A2/fr active IP Right Grant
- 1999-03-11 AU AU31837/99A patent/AU762493B2/en not_active Ceased
- 1999-03-11 CA CA002322663A patent/CA2322663A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999046371A3 (fr) | 2000-08-24 |
EP1070122A2 (fr) | 2001-01-24 |
WO1999046371A2 (fr) | 1999-09-16 |
AU762493B2 (en) | 2003-06-26 |
AU3183799A (en) | 1999-09-27 |
WO1999046371A9 (fr) | 2000-02-17 |
EP1070122A4 (fr) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6899870B1 (en) | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
AU742898B2 (en) | Fas ligand compositions for treatment of proliferative disorders | |
AU762493B2 (en) | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
PT1135469E (pt) | Método melhorado para a produção e purificação de vectores adenovirais | |
AU762615B2 (en) | Combination of radiotherapy and anti-angiogenic factors | |
US6251871B1 (en) | P16 expression constructs and their application in cancer therapy | |
US20010011078A1 (en) | DNA fragmentation factor involved in apoptosis | |
AU767880B2 (en) | Multigene vectors | |
Gómez-Navarro et al. | Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy | |
JP2005500247A (ja) | ヒトmda−7に関わる処置方法 | |
US6517828B1 (en) | C-CAM as an angiogenesis inhibitor | |
US20060193832A1 (en) | Use of the sodium iodine symporter to effect uptake of iodine | |
Shirakawa et al. | Drug‐resistant human bladder‐cancer cells are more sensitive to adenovirus‐mediated wild‐type p53 gene therapy compared to drug‐sensitive cells | |
JP4117367B2 (ja) | 腫瘍にあるサイクリンg1の発現を阻害する薬剤、その発現伝達体、およびベクター | |
US7625716B2 (en) | Methods for assessing p19-Arf interactions in cMyc | |
US8187586B2 (en) | Methods of inducing apoptosis in hyperproliferative cells | |
US6737052B1 (en) | Induction of programmed cell death by N5 gene | |
US20010036929A1 (en) | Xrcc3 is required for assembly of Rad51-complexes in vivo | |
US20020169126A1 (en) | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene | |
US20030138412A1 (en) | Inhibition of tumor growth and metastasis by N5 gene | |
EP1208114A2 (fr) | Induction de la mort cellulaire programmee par le gene n5 | |
Cerrato | Mechanisms of Ad-p53 induced apoptosis in human malignant glioma | |
Brown | Gene therapy for sporadic ovarian cancer | |
Lagace | Genomic Organization of the X-linked Inhibitor of Apoptosis and Identification of a Novel Testis-specific Homologue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |